PMAT variant rs3889348 is associated with metformin-induced gastrointestinal among Chinese Type 2 diabetes patients.

IF 1.9 4区医学 Q3 PHARMACOLOGY & PHARMACY

Pharmacogenomics Pub Date : 2023-07-01 Epub Date: 2023-07-17 DOI:10.2217/pgs-2023-0078

Ziqing Liu, Xiao Jia, Peng Wu, Benrui Wu, Ying Pan, Shao Zhong, Luhua Xiao, Yuehong Song, Jinbo Hu, Kaixin Zhou

{"title":"PMAT variant rs3889348 is associated with metformin-induced gastrointestinal among Chinese Type 2 diabetes patients.","authors":"Ziqing Liu, Xiao Jia, Peng Wu, Benrui Wu, Ying Pan, Shao Zhong, Luhua Xiao, Yuehong Song, Jinbo Hu, Kaixin Zhou","doi":"10.2217/pgs-2023-0078","DOIUrl":null,"url":null,"abstract":"Aim: This study examined intronic gene variants for their association with metformin intolerance in a Chinese population, focusing on the plasma monoamine transporter (PMAT) cis-protein expression quantitative trait loci (cis-eQTL) variant rs3889348. Methods: We recruited Type 2 diabetes patients from two hospitals and identified 111 metformin-intolerant patients using a questionnaire, and selected 206 metformin-tolerant patients from 2180 Type 2 diabetes mellitus patients. Genetic testing revealed an association between adverse gastrointestinal (GI) effects and SLC22A1 and PMAT. Results: The single-nucleotide polymorphism rs3889348 is associated with metformin-induced adverse GI effects. Each additional copy of the G allele increases the score by 5.23 (95% CI: 1.82-8.64; p = 0.003). Patients taking more transporter inhibitors were more likely to respond to metformin-induced GI intolerance (p = 0.042). Conclusion: PMAT cis-eQTL rs3889348 was significantly associated with metformin-induced adverse GI effects.","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacogenomics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/pgs-2023-0078","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/7/17 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: This study examined intronic gene variants for their association with metformin intolerance in a Chinese population, focusing on the plasma monoamine transporter (PMAT) cis-protein expression quantitative trait loci (cis-eQTL) variant rs3889348. Methods: We recruited Type 2 diabetes patients from two hospitals and identified 111 metformin-intolerant patients using a questionnaire, and selected 206 metformin-tolerant patients from 2180 Type 2 diabetes mellitus patients. Genetic testing revealed an association between adverse gastrointestinal (GI) effects and SLC22A1 and PMAT. Results: The single-nucleotide polymorphism rs3889348 is associated with metformin-induced adverse GI effects. Each additional copy of the G allele increases the score by 5.23 (95% CI: 1.82-8.64; p = 0.003). Patients taking more transporter inhibitors were more likely to respond to metformin-induced GI intolerance (p = 0.042). Conclusion: PMAT cis-eQTL rs3889348 was significantly associated with metformin-induced adverse GI effects.

查看原文本刊更多论文

在中国2型糖尿病患者中，PMAT变体rs3889348与二甲双胍诱导的胃肠道相关。

目的：本研究检测了中国人群中内含子基因变异与二甲双胍不耐受的关系，重点研究了血浆单胺转运蛋白（PMAT）顺式蛋白表达定量性状基因座（cis-eQTL）变异rs3889348。方法：我们从两家医院招募了2型糖尿病患者，通过问卷调查确定了111名二甲双胍不耐受患者，并从2180名2型糖尿病中选择了206名二甲双胍耐受患者。基因检测显示胃肠道（GI）不良反应与SLC22A1和PMAT之间存在关联。结果：单核苷酸多态性rs3889348与二甲双胍引起的胃肠道不良反应有关。每增加一个G等位基因拷贝，得分就会增加5.23（95%CI:1.82-8.64；p=0.003）。服用更多转运蛋白抑制剂的患者更有可能对二甲双胍诱导的胃肠道不耐受产生反应（p=0.042）。结论：PMAT顺式eQTL rs3889348与二甲双胍诱导的不良胃肠道反应显著相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pharmacogenomics 医学-药学

CiteScore

3.40

自引率

9.50%

发文量

审稿时长

4-8 weeks

期刊介绍： Pharmacogenomics (ISSN 1462-2416) is a peer-reviewed journal presenting reviews and reports by the researchers and decision-makers closely involved in this rapidly developing area. Key objectives are to provide the community with an essential resource for keeping abreast of the latest developments in all areas of this exciting field. Pharmacogenomics is the leading source of commentary and analysis, bringing you the highest quality expert analyses from corporate and academic opinion leaders in the field.